UAB CFRC Core A: Cell Model and Evaluation Core

UAB CFRC 核心 A：单元模型和评估核心

• 批准号: 10673355
• 负责人: George Martin Solomon
• 金额: $ 30.8万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10673355
• 关键词: Adopted; Animal Model; Animals; Area; Award; Biological Assay; Biological Models; Biology; Biopsy; Bronchi; Cell Culture System; Cell Culture Techniques; Cell model; Cells; Clinical; Clinical Trials; Collaborations; Complement; Complex; Cost Savings; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Development; Dyes; Epithelial Cells; Epithelium; Equipment; Evaluation; Excision; Fostering; Frequencies; Functional Imaging; Functional disorder; Funding; Gastrointestinal tract structure; Genetic; Health Insurance Portability and Accountability Act; Heterozygote; Human; Human Resources; Hydration status; Image; In Situ; In Vitro; Individual; Institutional Review Boards; Investigation; Ion Transport; Ions; Laboratories; Laboratory Research; Lung; Lung Transplantation; Measurement; Measures; Messenger RNA; Methodology; Methods; Modeling; Morbidity - disease rate; Mucociliary Clearance; Mucous body substance; Nose; Operative Surgical Procedures; Optical Coherence Tomography; Organ; Organoids; Pathogenesis; Pathway interactions; Permeability; Phenotype; Procedures; Process; Productivity; Property; Proteins; Publications; Pulmonary Cystic Fibrosis; Reagent; Rectum; Reproducibility; Research; Research Design; Research Personnel; Research Support; Resolution; Resources; Rights; Safety; Sampling; Science; Scientist; Sinus; Source; Standardization; Surface; Swelling; System; Techniques; Technology; Testing; Thick; Tissues; Trachea; Training; Translating; Translations; United States National Institutes of Health; Validation; Viscosity; Western Blotting; Work; airway epithelium; airway inflammation; airway surface liquid; anatomic imaging; body system; cystic fibrosis patients; digital; drug discovery; gene therapy; human subject; human tissue; improved; in vivo; innovation; insight; material transfer agreement; mortality; novel; novel therapeutics; protein expression; quality assurance; real-time images; rectal; repair strategy; repaired; repository; response; sample fixation; standard measure

PROJECT SUMMARY / ABSTRACT: P30 CORE A Well-differentiated human airway epithelial cells, model systems, and the assays that can be used with them are an instrumental model for understanding epithelial biology and are highly predictive of in vivo results in clinical trials. Primary cells can be used with methodologies that translate readily to assays of airway and epithelilal function in vivo, including measures of CFTR activity or other ion transporters, airway surface liquid depth and mucus hydration, mucus viscosity and transport. epithelial cell models further provide an excellent model for examining the biology of airway epithelial inflammation, which is key to the pathogenesis of cystic fibrosis (CF) lung disease. The purpose of Core A is to support the research of numerous P30 investigators that involves cell culture systems and to assist with established and innovative assays available to characterize cellular responses. Core A carries out three main functions as outlined in the Specific Aims. First, Core A procures (via interactions for clinical acquisition of samples via Core C), grows, and distributes well-differentiated primary human epithelial cells from a variety of tissue sources (lung, sinus, rectal, etc.) from CF and non-CF donors. This includes samples of cells from lung transplants, surgically excised nasal tissue, rectal biopsies, and nasal brushings obtained at UAB and from a large array of collaborating centers. Examination of novel expansion and differentiation techniques for primary cells is also a key function of the Core. Second, Core A conducts functional anatomic imaging of airway epithelia by 1-micron resolution Optical Coherence Tomography (μOCT) in vitro (primary cells of human or non-human origin) and ex vivo (intact full-thickness trachea, mainstem bronchi, and other tissues of human origin or comparable tissues from CF animal models, thus interfacing with Core B). μOCT allows for investigators to explore mucus flow and mucociliary interactions and is designated as a National Core due to its unique and important capabilities. Third, Core A performs and assists with measures of CFTR activity and expression. In addition to traditional assays of CFTR function (e.g, Ussing chambers), the Core supports innovative conductance assays, organoid swelling assays, and advanced PCR technology for investigating CFTR and other protein expression. Core A facilitates interdisciplinary collaborative research, provides resources that are beyond the expertise of individual research laboratories, fosters the sharing of ideas and experimental strategies, assists with technical troubleshooting, and maintains essential equipment that is and will be heavily utilized by P30 personnel and beyond. Cost savings are achieved by minimizing duplicate efforts of individual CF investigators, by the centralized purchase and usage of equipment, reagents, and supplies, as well as by maintaining a central repository for human epithelial tissue. On the whole, Core A provides significant expertise and resources to aid P30 investigators, fostering advancement of epithelial cell culture and innovative assays to understand CFTR pathogenesis and support rational drug discovery.

项目摘要/摘要：p30核心a